Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Non-Current Deferred Tax Liability (2025)

Quantum Biopharma's Non-Current Deferred Tax Liability history spans 1 years, with the latest figure at $1.2 million for Q4 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability changed N/A to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a N/A change, with the full-year FY2025 number at $1.2 million, changed N/A from a year prior.
  • Non-Current Deferred Tax Liability hit $1.2 million in Q4 2025 for Quantum Biopharma.
  • Over the last five years, Non-Current Deferred Tax Liability for QNTM hit a ceiling of $1.2 million in Q4 2025 and a floor of $1.2 million in Q4 2025.